Device and drug manufacturer
Issues relating to drug shortages; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94). Implementation of the Biologics Price Competition and Innovation Act (BPCIA) relating to biosimilar naming and reimbursement.
PHA - Pharmacy HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
BROWN RUDNICK LLP
601 13th Street, NW, 6th Floor, Washington, DC, 20005, US
HENRY W MENN LISA LAYMAN CHRISTOPHER BOWLIN HENRY W MENN LISA LAYMAN CHRISTOPHER BOWLIN